Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era

The atypical hemolytic uremic syndrome (aHUS) in the newborn is a rare disease, with high morbidity. Eculizumab, considered a first-line drug in older children, is not approved in neonates and in children weighing less than 5 kg. We present a 5-day-old female newborn, born at 36 weeks' twin ges...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Sara Madureira, Teixeira, Rita Pissarra, Rocha, Gustavo, Soares, Paulo, Guimaraes, Hercilia, Santos, Paulo, Jardim, Joana, Barreira, João Luís, Pinto, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical Publishers, Inc. 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221835/
https://www.ncbi.nlm.nih.gov/pubmed/34178424
http://dx.doi.org/10.1055/s-0041-1731057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221835/
https://www.ncbi.nlm.nih.gov/pubmed/34178424
http://dx.doi.org/10.1055/s-0041-1731057

Ejemplares similares